IE40187B1 - Process for the preparation of pyrogen-free sub-unit vaccine - Google Patents

Process for the preparation of pyrogen-free sub-unit vaccine

Info

Publication number
IE40187B1
IE40187B1 IE2141/74A IE214174A IE40187B1 IE 40187 B1 IE40187 B1 IE 40187B1 IE 2141/74 A IE2141/74 A IE 2141/74A IE 214174 A IE214174 A IE 214174A IE 40187 B1 IE40187 B1 IE 40187B1
Authority
IE
Ireland
Prior art keywords
active agent
density gradient
pyrogen
preparation
vol
Prior art date
Application number
IE2141/74A
Other languages
English (en)
Other versions
IE40187L (en
Original Assignee
Flockhart & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flockhart & Co filed Critical Flockhart & Co
Publication of IE40187L publication Critical patent/IE40187L/xx
Publication of IE40187B1 publication Critical patent/IE40187B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IE2141/74A 1973-10-18 1974-10-17 Process for the preparation of pyrogen-free sub-unit vaccine IE40187B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB48685/73A GB1486557A (en) 1973-10-18 1973-10-18 Process for the preparation of pyrogen-free sub-unit vaccine

Publications (2)

Publication Number Publication Date
IE40187L IE40187L (en) 1975-04-18
IE40187B1 true IE40187B1 (en) 1979-03-28

Family

ID=10449549

Family Applications (1)

Application Number Title Priority Date Filing Date
IE2141/74A IE40187B1 (en) 1973-10-18 1974-10-17 Process for the preparation of pyrogen-free sub-unit vaccine

Country Status (15)

Country Link
JP (1) JPS5082228A (enExample)
AT (1) AT334524B (enExample)
BE (1) BE821175A (enExample)
CA (1) CA1050886A (enExample)
CH (1) CH611518A5 (enExample)
DE (1) DE2449530C2 (enExample)
DK (1) DK138581B (enExample)
FR (1) FR2248054B1 (enExample)
GB (1) GB1486557A (enExample)
IE (1) IE40187B1 (enExample)
IL (1) IL45870A (enExample)
NL (1) NL181553C (enExample)
NO (1) NO142024C (enExample)
SE (1) SE426439B (enExample)
ZA (1) ZA746398B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK276380A (da) * 1979-07-09 1981-01-10 Univ Iowa State Res Found Inc Fremgangsmaade til fremstilling af en vaccine mod infektioes kvaeg-rhinotracheitis
FR2470795A1 (fr) * 1979-12-07 1981-06-12 Pasteur Institut Procede de purification de particules d'origine biologique, notamment de l'antigene de surface du virus de l'hepatite b (aghbs) et les produits obtenus
FR2475572A1 (fr) * 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
FR2483779A1 (fr) 1980-06-05 1981-12-11 Synthelabo Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins
DE19938767C2 (de) * 1999-08-16 2002-10-24 Tad Pharma Gmbh Spaltimpfstoffe
BR0114392A (pt) * 2000-10-02 2003-09-02 Glaxosmithkline Biolog Sa Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsv

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3519400A (en) * 1967-01-25 1970-07-07 Atomic Energy Commission Method of centrifugal separation and recovery of chemical species utilizing a liquid medium

Also Published As

Publication number Publication date
DK138581B (da) 1978-10-02
IE40187L (en) 1975-04-18
IL45870A0 (en) 1974-12-31
GB1486557A (en) 1977-09-21
AU7444974A (en) 1976-04-29
CA1050886A (en) 1979-03-20
IL45870A (en) 1978-03-10
DK543974A (enExample) 1975-06-16
DE2449530C2 (de) 1985-08-08
NO142024C (no) 1980-06-18
DE2449530A1 (de) 1975-04-30
NO743758L (enExample) 1975-05-12
NL181553C (nl) 1987-09-16
FR2248054B1 (enExample) 1978-07-28
AT334524B (de) 1976-01-25
CH611518A5 (en) 1979-06-15
NL181553B (nl) 1987-04-16
ZA746398B (en) 1976-06-30
FR2248054A1 (enExample) 1975-05-16
BE821175A (fr) 1975-04-17
NO142024B (no) 1980-03-10
ATA835074A (de) 1976-05-15
SE426439B (sv) 1983-01-24
NL7413642A (nl) 1975-04-22
JPS5082228A (enExample) 1975-07-03
DK138581C (enExample) 1979-03-12
SE7413113L (enExample) 1975-04-21

Similar Documents

Publication Publication Date Title
IE811595L (en) Synthetic peptide antigens
SE8701413L (sv) Expression och rening av en htlv-iii gag/env-gen protein
ES8404186A1 (es) "un procedimiento para obtener al menos un polipeptido que presenta la antigenicidad de los antigenos e del virus de la hepatitis b".
EP0342860A3 (en) Novel protein, sequences containing the gene therefore, vectors, methods of preparation and use
FI905184A0 (fi) Kimeriska glykoproteiner som innehaoller immunogeniska delar av human parainfluensa-virus typ 3.
ATA852374A (de) Verfahren zur herstellung von neuen 1,2-benzisoxazol-derivaten
IE40187B1 (en) Process for the preparation of pyrogen-free sub-unit vaccine
DK160274C (da) Fremgangsmaade til fremstilling af 4'-deoxydaunorubicin eller 4'-deoxydoxorubicin
ES8104405A1 (es) Procedimiento para preparar una vacuna de virus de gripe
AT320100B (de) Verfahren zur Herstellung von neuen Azoreaktivfarbstoffen
GB1292803A (en) Improvements relating to the production of antigens
GB1461188A (en) Live influenza virus vaccines and preparation thereof
IE39521B1 (en) Process for the preparation of 2,2,6,6,-tetramethyl-4-oxopiperidine
ES432385A1 (es) Un metodo de obtener una cepa de virus de la gripe.
DK136827B (da) 17beta-hyroxy-3-oxo-4,6-steroiddien-17alfa-methylmalonsyrederivater til brug som mellemprodukter til fremstilling af 17-spirolactoner samt fremgangsmåde til fremstilling af mellemprodukterne.
DK115349B (da) Fremgangsmåde til fremstilling af en som vaccine anvendelig, inaktiveret virussuspension, der indeholder et virus, som er isoleret fra in vitro dyrkede nyreceller fra en hundehvalp, der lider af rhinitis eller bronkopneumoni.
GB1252092A (enExample)
JPS54101833A (en) Purification of blue dyestuff extract
SHIMOJO et al. The nature of tumor antigen of adenovirus type 12 and its formation in cultured cells after infection
ES8100239A1 (es) Procedimiento para preparar alqueniloxifenol insaturado en b,8
ATA890474A (de) Verfahren zur herstellung von neuen, ketimingruppen enthaltenden prapolymeren
FR2261779A1 (en) Anti-rabies vaccine - obtd. from rabies virus grown on foetal calf kidney cells in a synthetic serum-free medium
JPS5423119A (en) Erythrocyte for haemagglutination test
GB958574A (en) Clostridium perfringens ª‰-toxoid vaccines
FR2290220A2 (fr) Nouveau vaccin antirabique